PeproMene Bio
Tracked across 2 events · 12 articles · First seen May 28, 2026 · Last active Sep 08, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: As the developer of PMB-CT01, PeproMene Bio is the central entity in this event, benefiting from positive clinical trial results that validate its therapeutic approach and potentially increase its market value and future commercialization prospects.
May 28, 2026 · 6 articles
Tech
PeproMene Bio announced the publication in The Lancet of results from its Phase 1 clinical trial of PMB-CT01, a first-in-class BAFF-R-targeted CAR T-cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The trial…
Impact: As the developer of PMB-CT01, PeproMene Bio is the primary beneficiary. The positive results and publication could significantly boost its prospects for funding, partnerships, and eventual commercialization.
Jul 20, 2026 · 6 articles
100
PeproMene Bio published resultsPeproMene Bio publishes...
60
Institute for Follicular Lymphoma Innovation committed funding PeproMene BioPeproMene Bio publishes...
ERGEN INTELLIGENCE
Track PeproMene Bio live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard